{"id":"W4401784358","doi":"10.1080/23995270.2024.2380247","title":"A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy","year":2024,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"AstraZeneca; Omeros Corporation; Alexion Pharmaceuticals; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003463883,0.0001851343,0.0003291276,0.0000472296,0.00007623922,0.00002168328,0.0001094631,0.00004455169,0.00006546055],"category_scores_gemma":[0.00004959224,0.0000744242,0.0005027758,0.0002132197,0.0001036682,0.00004578558,0.00001968465,0.00004845269,0.000001661839],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004563259,"about_ca_system_score_gemma":0.000211115,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000055176,"about_ca_topic_score_gemma":0.00002027032,"domain_scores_codex":[0.9990846,0.00004711111,0.0002439497,0.0001946216,0.0002709723,0.0001587742],"domain_scores_gemma":[0.9990649,0.0002325968,0.00009717352,0.000433946,0.00009233408,0.00007904365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.3407033,0.01013538,0.1990343,0.008187519,0.004881579,0.0002491054,0.01083053,0.00007109137,0.0003265939,0.001168162,0.04592832,0.3784841],"study_design_scores_gemma":[0.03465078,0.006993634,0.8350562,0.001541262,0.004162775,0.000004545508,0.003663923,0.0000925999,0.0005147351,0.00007952109,0.112983,0.0002569453],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9000318,0.09286509,0.00001019964,0.0007232832,0.0005461666,0.002214554,0.003506691,0.00003974745,0.00006246048],"genre_scores_gemma":[0.9967366,0.001273985,0.00002813913,0.0001534794,0.0007325707,0.0002848872,0.0004026322,0.0000331139,0.0003545189],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6360219,"threshold_uncertainty_score":0.3034931,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005686959444619518,"score_gpt":0.2434480502845588,"score_spread":0.2377610908399392,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}